(4-(Bis(4-Fluorophenyl)Methyl)Piperazin-1-yl)(Cyclohexyl) methanone hydrochloride (LDK1229): A new cannabinoid CB1 receptor inverse agonist from the class of benzhydryl piperazine analogs

Molecular Pharmacology

Volumn 87, Issue 2, 2015, Pages 197-206

  Mahmoud, Mariam M ^a   Olszewska, Teresa ^b   Liu, Hui ^b   Shore, Derek M ^c   Hurst, Dow P ^c   Lu, Dai ^b   Kendall, Debra A ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [BIS(4 FLUOROPHENYL)METHYL] 4 TOSYLPIPERAZINE; 4 [BIS(4 FLUOROPHENYL)METHYL]PIPERAZIN 1 YL](CYCLOHEXYL)METHANONE; BENZHYDRYL DERIVATIVE; CANNABINOID RECEPTOR AGONIST; FLUNARIZINE; G PROTEIN COUPLED RECEPTOR; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); PIPERAZINE DERIVATIVE; RIMONABANT; UNCLASSIFIED DRUG; CANNABINOID; CANNABINOID 1 RECEPTOR; PIPERAZINE; PROTEIN BINDING;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROPHILICITY; STRUCTURE ACTIVITY RELATION; AGONISTS; ANIMAL; BOVINE; CHEMISTRY; HEK293 CELL LINE; INVERSE AGONISM; METABOLISM; PHYSIOLOGY; PROTEIN SECONDARY STRUCTURE;

ANIMALS; BENZHYDRYL COMPOUNDS; CANNABINOIDS; CATTLE; DRUG INVERSE AGONISM; HEK293 CELLS; HUMANS; PIPERAZINES; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; RECEPTOR, CANNABINOID, CB1;

EID: 84919723300     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.095471     Document Type: Article

References (74)

1. Ahn KH, Bertalovitz AC, Mierke DF, and Kendall DA (2009) Dual role of the second extracellular loop of the cannabinoid receptor 1: ligand binding and receptor localization. Mol Pharmacol 76:833-842.
2. Ahn KH, Mahmoud MM, and Kendall DA (2012) Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation. J Biol Chem 287:12070-12082
3. Ballesteros JA, Jensen AD, Liapakis G, Rasmussen SG, Shi L, Gether U, and Javitch JA (2001) Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J Biol Chem 276:29171-29177.
4. Barnett-Norris J, Hurst DP, Buehner K, Ballesteros JA, Guarnieri F, and Reggio PH (2002) Agonist alkyl tail interaction with cannabinoid CB1 receptor V6.43/I6.46 groove induces a helix 6 active conformation. Int J Quantum Chem 88:76-86.
5. Basu S and Dittel BN (2011) Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease. Immunol Res 51:26-38.
6. Bátkai S, Járai Z, Wagner JA, Goparaju SK, Varga K, Liu J, Wang L, Mirshahi F, Khanolkar AD, and Makriyannis A et al. (2001) Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 7:827-832.
7. Bosgraaf L, van Haastert PJ, and Bretschneider T (2009) Analysis of cell movement by simultaneous quantification of local membrane displacement and fluorescent intensities using Quimp2. Cell Motil Cytoskeleton 66:156-165.
8. Bouaboula M, Poinot-Chazel C, Marchand J, Canat X, Bourrié B, Rinaldi-Carmona M, Calandra B, Le Fur G, and Casellas P (1996) Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogenactivated protein kinase and induction of Krox-24 expression. Eur J Biochem 237:704-711.
9. Chen C and Okayama H (1987) High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 7:2745-2752.
10. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
11. Chorvat RJ (2013) Peripherally restricted CB1 receptor blockers. Bioorg Med Chem Lett 23:4751-4760.
12. Clark DE (2005) Computational prediction of blood-brain barrier permeation. Annu Rep Med Chem 40:403-415.
13. Cotecchia S, Exum S, Caron MG, and Lefkowitz RJ (1990) Regions of the alpha 1-adrenergic receptor involved in coupling to phosphatidylinositol hydrolysis and enhanced sensitivity of biological function. Proc Natl Acad Sci USA 87:2896-2900.
14. Croci T, Manara L, Aureggi G, Guagnini F, Rinaldi-Carmona M, Maffrand JP, Le Fur G, Mukenge S, and Ferla G (1998) In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Br J Pharmacol 125:1393-1395.
15. D'Antona AM, Ahn KH, and Kendall DA (2006) Mutations of CB1 T210 produce active and inactive receptor forms: correlations with ligand affinity, receptor stability, and cellular localization. Biochemistry 45:5606-5617.
16. De Lean A, Stadel JM, and Lefkowitz RJ (1980) A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled betaadrenergic receptor. J Biol Chem 255:7108-7117.
17. Després JP, Golay A, and Sjöström L; Rimonabant in Obesity-Lipids Study Group (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353:2121-2134.
18. Di Marzo V and Matias I (2005) Endocannabinoid control of food intake and energy balance. Nat Neurosci 8:585-589.
19. Dormann D, Libotte T, Weijer CJ, and Bretschneider T (2002) Simultaneous quantification of cell motility and protein-membrane-association using active contours. Cell Motil Cytoskeleton 52:221-230.
20. Engeli S, Böhnke J, Feldpausch M, Gorzelniak K, Janke J, Bátkai S, Pacher P, Harvey-White J, Luft FC, and Sharma AM et al. (2005) Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54:2838-2843.
21. Fay JF, Dunham TD, and Farrens DL (2005) Cysteine residues in the human cannabinoid receptor: only C257 and C264 are required for a functional receptor, and steric bulk at C386 impairs antagonist SR141716A binding. Biochemistry 44:8757-8769.
22. Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P, Bouaboula M, Shire D, Le Fur G, and Casellas P (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232:54-61.
23. Gérard CM, Mollereau C, Vassart G, and Parmentier M (1991) Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 279:129-134.
24. Gether U and Kobilka BK (1998) G protein-coupled receptors. II. Mechanism of agonist activation. J Biol Chem 273:17979-17982.
25. Ghanouni P, Steenhuis JJ, Farrens DL, and Kobilka BK (2001) Agonist-induced conformational changes in the G-protein-coupling domain of the beta 2 adrenergic receptor. Proc Natl Acad Sci USA 98:5997-6002.
26. Hildebrand PW, Scheerer P, Park JH, Choe HW, Piechnick R, Ernst OP, Hofmann KP, and Heck M (2009) A ligand channel through the G protein coupled receptoropsin. PLoS ONE 4:e4382.
27. Howlett AC (1995) Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol 35:607-634.
28. Howlett AC (2005) Cannabinoid receptor signaling. Handb Exp Pharmacol 168:53-79.
29. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, and Porrino LJ (2004) Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 47 (Suppl 1):345-358.
30. Howlett AC and Fleming RM (1984) Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol Pharmacol 26:532-538.
31. Hurst D, Umejiego U, Lynch D, Seltzman H, Hyatt S, Roche M, McAllister S, Fleischer D, Kapur A, and Abood M et al. (2006) Biarylpyrazole inverse agonists at the cannabinoid CB1 receptor: importance of the C-3 carboxamide oxygen/lysine3.28(192) interaction. J Med Chem 49:5969-5987.
32. Hurst DP, Grossfield A, Lynch DL, Feller S, Romo TD, Gawrisch K, Pitman MC, and Reggio PH (2010) A lipid pathway for ligand binding is necessary for a cannabinoid G protein-coupled receptor. J Biol Chem 285:17954-17964.
33. Hurst DP, Lynch DL, Barnett-Norris J, Hyatt SM, Seltzman HH, Zhong M, Song ZH, Nie J, Lewis D, and Reggio PH (2002) N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol Pharmacol 62:1274-1287.
34. Janero DR (2012) Cannabinoid-1 receptor (CB1R) blockers as medicines: Beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists. Expert Opin Emerg Drugs 17:17-29.
35. Janero DR and Makriyannis A (2009) Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin Emerg Drugs 14:43-65.
36. Jones D (2008) End of the line for cannabinoid receptor 1 as an anti-obesity target? Nat Rev Drug Discov 7:961-962.
37. Kenakin T (1995) Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 16:232-238.
38. Landsman RS, Burkey TH, Consroe P, Roeske WR, and Yamamura HI (1997) SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur J Pharmacol 334:R1-R2.
39. Lange JH and Kruse CG (2005) Keynote review: medicinal chemistry strategies to CB1 cannabinoid receptor antagonists. Drug Discov Today 10:693-702.
40. Lange JH and Kruse CG (2008) Cannabinoid CB1 receptor antagonists in therapeutic and structural perspectives. Chem Rec 8:156-168.
41. Leterrier C, Bonnard D, Carrel D, Rossier J, and Lenkei Z (2004) Constitutive endocytic cycle of the CB1 cannabinoid receptor. J Biol Chem 279:36013-36021.
42. Mackie K (2006) Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 46:101-122.
43. Marcu J, Shore DM, Kapur A, Trznadel M, Makriyannis A, Reggio PH, and Abood ME (2013) Novel insights into CB1 cannabinoid receptor signaling: a key interaction identified between the extracellular-3 loop and transmembrane helix 2. J Pharmacol Exp Ther 345:189-197.
44. Marion S, Weiner DM, and Caron MG (2004) RNA editing induces variation in desensitization and trafficking of 5-hydroxytryptamine 2c receptor isoforms. J Biol Chem 279:2945-2954.
45. Martini L, Waldhoer M, Pusch M, Kharazia V, Fong J, Lee JH, Freissmuth C, and Whistler JL (2007) Ligand-induced down-regulation of the cannabinoid 1 receptor is mediated by the G-protein-coupled receptor-associated sorting protein GASP1. FASEB J 21:802-811.
46. McAllister SD, Hurst DP, Barnett-Norris J, Lynch D, Reggio PH, and Abood ME (2004) Structural mimicry in class A G protein-coupled receptor rotamer toggle switches: the importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation. J Biol Chem 279:48024-48037.
47. McAllister SD, Rizvi G, Anavi-Goffer S, Hurst DP, Barnett-Norris J, Lynch DL, Reggio PH, and Abood ME (2003) An aromatic microdomain at the cannabinoid CB (1) receptor constitutes an agonist/inverse agonist binding region. J Med Chem 46:5139-5152.
48. McWhinney C, Wenham D, Kanwal S, Kalman V, Hansen C, and Robishaw JD (2000) Constitutively active mutants of the alpha(1a)- and the alpha(1b)-adrenergic receptor subtypes reveal coupling to different signaling pathways and physiological responses in rat cardiac myocytes. J Biol Chem 275:2087-2097.
49. Meschler JP, Kraichely DM, Wilken GH, and Howlett AC (2000) Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB (1) cannabinoid receptor. Biochem Pharmacol 60:1315-1323.
50. Moreira FA and Crippa JA (2009) The psychiatric side-effects of rimonabant. Rev Bras Psiquiatr 31:145-153.
51. Muccioli GG and Lambert DM (2005) Current knowledge on the antagonists and inverse agonists of cannabinoid receptors. Curr Med Chem 12:1361-1394.
52. Pagotto U, Marsicano G, Cota D, Lutz B, and Pasquali R (2006) The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27:73-100.
53. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, and Stenkamp RE et al. (2000) Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289:739-745.
54. Park JH, Scheerer P, Hofmann KP, Choe HW, and Ernst OP (2008) Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature 454:183-187.
55. Pei Y, Mercier RW, Anday JK, Thakur GA, Zvonok AM, Hurst D, Reggio PH, Janero DR, and Makriyannis A (2008) Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation. Chem Biol 15:1207-1219.
56. Pertwee RG (2005) Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 76:1307-1324.
57. Pertwee RG (2006) Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 147 (Suppl 1): S163-S171.
58. Picone RP, Khanolkar AD, Xu W, Ayotte LA, Thakur GA, Hurst DP, Abood ME, Reggio PH, Fournier DJ, and Makriyannis A (2005) (-)-7'-Isothiocyanato-11-hydroxy-19,19-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. Mol Pharmacol 68:1623-1635.
59. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Néliat G, and Caput D et al. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244.
60. Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M, and Calandra B et al. (1998a) SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 284:644-650.
61. Rinaldi-Carmona M, Le Duigou A, Oustric D, Barth F, Bouaboula M, Carayon P, Casellas P, and Le Fur G (1998b) Modulation of CB1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the Chinese hamster ovary cell expression system. J Pharmacol Exp Ther 287:1038-1047.
62. Rozenfeld R and Devi LA (2008) Regulation of CB1 cannabinoid receptor trafficking by the adaptor protein AP-3. FASEB J 22:2311-2322.
63. Scheerer P, Park JH, Hildebrand PW, Kim YJ, Krauss N, Choe HW, Hofmann KP, and Ernst OP (2008) Crystal structure of opsin in its G-protein-interacting conformation. Nature 455:497-502.
64. Shim JY, Bertalovitz AC, and Kendall DA (2012) Probing the interaction of SR141716A with the CB1 receptor. J Biol Chem 287:38741-38754.
65. Silvestri C and Di Marzo V (2012) Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders. Expert Opin Investig Drugs 21:1309-1322.
66. Silvestri C, Ligresti A, and Di Marzo V (2011) Peripheral effects of the endocannabinoid system in energy homeostasis: adipose tissue, liver and skeletal muscle. Rev Endocr Metab Disord 12:153-162.
67. Slipetz DM, O'Neill GP, Favreau L, Dufresne C, Gallant M, Gareau Y, Guay D, Labelle M, and Metters KM (1995) Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Mol Pharmacol 48:352-361.
68. Song ZH and Bonner TI (1996) A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. Mol Pharmacol 49:891-896.
69. Traynor K (2007) Panel advises against rimonabant approval. Am J Health Syst Pharm 64:1460-1461.
70. Turu G and Hunyady L (2010) Signal transduction of the CB1 cannabinoid receptor. J Mol Endocrinol 44:75-85.
71. Vemuri VK, Janero DR, and Makriyannis A (2008) Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome. Physiol Behav 93:671-686.
72. Visiers I, Ebersole BJ, Dracheva S, Ballesteros J, Sealfon SC, and Weinstein H (2002) Structural motifs as functional microdomains in G-protein-coupled receptors: energetic considerations in the mechanism of activation of the serotonin 5-HT2A receptor by disruption of the ionic lock of the arginine cage. Int J Quantum Chem 88:65-75.
73. Wade SM, Lan K, Moore DJ, and Neubig RR (2001) Inverse agonist activity at the alpha(2A)-adrenergic receptor. Mol Pharmacol 59:532-542.
74. Weïwer M, Bittker JA, Lewis TA, Shimada K, Yang WS, MacPherson L, Dandapani S, Palmer M, Stockwell BR, and Schreiber SL et al. (2012) Development of small-molecule probes that selectively kill cells induced to express mutant RAS. Bioorg Med Chem Lett 22:1822-1826.